Replies to post #9413 on Seelos Therapeutics Inc (SEEL)

[value1008]

If APRI announced in Q4 a big partner or two for rest of Europe with 1) major upfront license fee revenues of $25M-$30M and 2) milestone payments totaling over time $100M or more, this stock would be up to $4-$5 in a jiffy. Yeah, that's dangling a big carrot, but quite feasible and reasonable.